FRANKFURT (dpa-AFX) - The successful preclinical development of a biosimilar for Sanofi's blockbuster drug Dupixent boosted Formycon shares on Monday morning. On the Tradegate trading platform, the stock soared by around eleven percent to 23 euros compared to the Xetra close. This marks a renewed recovery attempt for the shares, which had fallen to their lowest level since 2020 at the beginning of November. As of Friday's close in 2025, they were down around 60 percent.
With the completion of the so-called "Technical Proof of Similarity" (TPoS), the active ingredient FYB208 demonstrated high analytical comparability to the reference drug Dupixent, the SDax-listed company announced.
This now paves the way for the start of clinical development, which could eventually lead to approval after several years. The patent protection for Sanofi's Dupixent expires in 2031, at which point generic and biosimilar manufacturers will be able to enter the market.
The French pharmaceutical group generates billions in revenue with Dupixent, which is used to treat chronic inflammatory diseases such as COPD, asthma, and neurodermatitis./mis/ag/stk
